• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • #GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • 0 CME Hours
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • #GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
#Grand Rounds

Results from the OPTIMIST Study: Does Interaction with a Pharmacist Prevent Readmissions and ED Visits?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE: 

  • Approximately 5% of hospital admissions can be attributed to drug reactions 
  • Ravn-Nielsen et al. (JAMA Int Med, 2018) examined whether multifaceted pharmacist interventions can prevent further hospital and emergency department visits

METHODS: 

  • Randomized clinical multicenter study (RCT) 
  • Odense Pharmacist Trial Investigating Medication Interventions at Sector Transfer (OPTIMIST), conducted in Denmark  
  • Participants: Medical patients in an acute admission ward, ≥18 years and were using 5 or more medications 
  • The medication review and patient interviews were conducted in the hospital and followed up in collaboration with primary care 
  • The patients were randomized into the following groups 
    • Usual care (no intervention) 
    • Basic intervention: Structured, patient-centered medication by a clinical pharmacist after (1)admission; (2)lab data available; (3)primary medical admission note written 
    • Extended intervention: (1)medication review as above; (2) three motivational interviews; (3)follow-up with primary care physician, pharmacy, and nursing home) 
  • The primary outcomes  
    • Readmission within 30 or 180 days  
    • Emergency Department (ED) visits within 180 days 
  • Primary composite endpoint: readmission or ED visit within 180 days 
  • Secondary outcomes  
    • Drug-related readmissions within 30 and 180 days after inclusion 
    • All-cause mortality and drug-related mortality

RESULTS: 

  • 1,499 patients were enrolled in the study 
  • Extended intervention resulted in  
    • Decreased readmission within 30 days (hazard ratio [HR], 0.62; 95% CI, 0.46-0.84) 
    • Decreased readmission within 180 days (HR, 0.75; 95% CI, 0.62-0.90)  
    • Decreased primary composite endpoint (HR, 0.77; 95% CI, 0.64-0.93) 
  • There was no significant reduction in drug-related readmissions 
    •  Within 30 days (HR, 0.65; 95% CI, 0.39-1.09)  
    •  Within 180 days (HR, 0.80; 95% CI, 0.59-1.08)  
  • There was no significant reduction in deaths (HR, 0.83; 95% CI, 0.22-3.11) 

CONCLUSION: 

  • Interaction with a hospital pharmacist, using a multi-faceted approach, may reduce the number of ED visits and hospital readmissions 
  • Authors acknowledge potential “political or other barriers toward allocating a large budget for such intervention”

Learn More – Primary Sources: 

Effect of an In-Hospital Multifaceted Clinical Pharmacist Intervention on the Risk of Readmission

image_pdfFavoriteLoadingFavorite

< Previous
All #Grand Rounds Posts
Next >

Related ObG Topics:

Where Does all the Money Go? Estimated Administrative Costs Related to Physician Billing Activities
Do Pay for Performance Incentives Enhance Hospital Performance?
Herb-drug Interactions – How Severe are Potential Adverse Drug Reactions?

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • #Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

ObG Library

  • Hysteroscopy
  • Fertility
  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site